TRX vs. SFR, NAK, EGI, IMG, EDG, MTA, NGR, RRS, NG, and WPM
Should you be buying Tissue Regenix Group stock or one of its competitors? The main competitors of Tissue Regenix Group include Severfield (SFR), Nakama Group plc (NAK.L) (NAK), (EGI.L) (EGI), 532753 (IMG.L) (IMG), 651814 (EDG.L) (EDG), ArcelorMittal (MTA), Nature Group (NGR), Randgold Resources (RRS), National Grid (NG), and Wheaton Precious Metals (WPM). These companies are all part of the "precious metals" industry.
Tissue Regenix Group vs.
Severfield (LON:SFR) and Tissue Regenix Group (LON:TRX) are both small-cap industrials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, community ranking, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.
Severfield has higher revenue and earnings than Tissue Regenix Group. Tissue Regenix Group is trading at a lower price-to-earnings ratio than Severfield, indicating that it is currently the more affordable of the two stocks.
In the previous week, Severfield had 1 more articles in the media than Tissue Regenix Group. MarketBeat recorded 1 mentions for Severfield and 0 mentions for Tissue Regenix Group. Severfield's average media sentiment score of 1.40 beat Tissue Regenix Group's score of 0.00 indicating that Severfield is being referred to more favorably in the media.
Severfield received 64 more outperform votes than Tissue Regenix Group when rated by MarketBeat users. Likewise, 76.09% of users gave Severfield an outperform vote while only 69.53% of users gave Tissue Regenix Group an outperform vote.
66.9% of Severfield shares are held by institutional investors. Comparatively, 37.0% of Tissue Regenix Group shares are held by institutional investors. 4.4% of Severfield shares are held by insiders. Comparatively, 47.3% of Tissue Regenix Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Severfield has a net margin of 3.43% compared to Tissue Regenix Group's net margin of -3.46%. Severfield's return on equity of 7.25% beat Tissue Regenix Group's return on equity.
Severfield has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Tissue Regenix Group has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.
Summary
Severfield beats Tissue Regenix Group on 12 of the 15 factors compared between the two stocks.
Get Tissue Regenix Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tissue Regenix Group Competitors List
Related Companies and Tools
This page (LON:TRX) was last updated on 1/21/2025 by MarketBeat.com Staff
